Tumor Immune Microenvironment In Lung Cancer: Is It Prime Time To Add Immunological Prognostic Markers To TNM Classification? | 25076
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Tumor-associated immune responses have polarized effects in regulating tumor growth. Although a clear association
has been shown between the tumor immune response and clinical outcome in colorectal and ovarian cancers, the role
of immune markers for stratifying prognosis in non-small cell lung cancer (NSCLC) is less defined. As a first step, our
laboratory performed a comprehensive review of the prognostic significance of published immune markers in the tumor
microenvironment and peripheral blood of NSCLC patients. To identify prognostic immune genes, we reviewed all published
gene-profiling studies in NSCLC and delineated the significance of immune genes by doing subanalysis on the microarray
database of the NIH Director's Challenge study from our institution. These results were published (Clinical Cancer Research
2011) and currently highly cited. We then performed extensive analysis of the immune responses in early-stage lung adeno and
squamous cell cancers (n=1600). Parts of these results were published in JCO, Journal of Clinical Oncology, 2013. Subsequently,
we identified the aggressive morphological subtypes of lung adenocarcinoma associations with specific immunological profile.
These combined data provided solid evidence that immunological composition of lung cancers can provide more biological
and prognostic information than current TNM staging. We propose that it is time to validate these results from a multi-national
cohort and consider incorporating ?immunological score? into current TNM classification for lung cancer. Furthermore, this
score will play a greater role in the management of emerging immunotherapies.
Prasad S Adusumilli has completed his M.B.B.S. at the age of 22 years from Guntur Medical College and postdoctoral studies from AIIMS, New Delhi, Southampton
University, UK and from Memorial Sloan Kettering Cancer Center (MSKCC) and University of Pittsburgh, USA. He is now the Deputy Chief of Thoracic Surgery
at the MSKCC and Member in Center for Cell Engineering at MSKCC. He has published more than 100 papers in reputed journals including JCO and JNCI. He
is invited to be the Deputy Chief Editor for Molecular Therapy Oncolytics Journal (Nature Group Publication) serves as an editorial board member of PLOSOne.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals